The impairment masks a solid operational quarter. Focus on organic growth acceleration (4.5%) and FY2027 guidance implying mid-single-digit revenue growth and margin expansion. Watch for integration updates on Attune Medical and Vivasure on the earnings call.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $54.37entry
- T+1 · 6mo ago +1.38%α +0.55% · $55.12
- T+5 · 6mo ago +4.86%α +3.35% · $57.01
- T+20 · 6mo ago +21.17%α +18.03% · $65.88
- T+60 · 4mo ago +59.63%α +55.80% · $86.79
Price Chart
How similar events traded
Executive Summary
Haemonetics Q4 FY2026 revenue grew 4.8% YoY to $346.4M, beating estimates, while adjusted EPS of $1.29 edged past consensus. GAAP net loss of $20.1M was driven by a $77.2M impairment of intangible assets from the Attune Medical acquisition. FY2027 guidance calls for 4-7% reported revenue growth and 50-100bps adjusted operating margin expansion, signaling underlying business momentum.
Key Financial Metrics
Key Facts
- Q4 revenue $346.4M, +4.8% YoY; organic revenue growth 4.5%; organic ex-CSL growth 8.6%
- Q4 GAAP EPS -$0.44 (net loss $20.1M) vs $1.17 in prior year, due to $77.2M impairment charge
- Q4 adjusted EPS $1.29, up 4.0% YoY; adjusted net income $59.7M, down 3.0%
- FY2026 full year revenue $1.334B, -2.0% YoY; adjusted EPS $4.96, +8.5%
- FY2027 guidance: reported revenue growth 4-7%, organic revenue growth 3-6%, adjusted operating margin expansion 50-100bps
- Repurchased $100M in shares in Q4; $325M remaining under $500M authorization
Financial Impact
Non-cash impairment of $77.2M drove GAAP loss; adjusted operations remained profitable with $84.5M adjusted operating income.
Risk Factors
- Integration challenges from Attune Medical and Vivasure acquisitions
- Interventional Technologies segment declined 10.3% organic in Q4
- Tariff impacts on adjusted gross margin
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000313143-26-000031 |
| Document: hae-20260507.htm | 0000313143-26-000031 |
| Document: 0000313143-26-000031-index-headers.html | 0000313143-26-000031 |
| Document: 0000313143-26-000031-index.html | 0000313143-26-000031 |
| Document: 0000313143-26-000031.txt | 0000313143-26-000031 |
| 8-K Data (Synthetic) | 0000313143-26-000031 |
Track record
14 reports on HAE
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +2.44% at T+5 after the Oct 20, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $122.71 Now $121.34 −1.12% settles Nov 19
- Nov 5, 202611d ago 8-K Bullish 6/10 No price data
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $124.11 to $122.71 Now $121.34 −2.23% ▼ −1.13% −4.42% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $117.11 to $119.97 Now $121.34 +3.61% ▲ +2.44% +2.89% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $118.21 to $119.97 Now $121.34 +2.65% ▲ +1.49% +1.41% vs SPY
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $122.06 to $118.73 Now $121.34 −0.59% ▼ −2.73% −1.23% vs SPY
- Oct 8, 20265w ago 8-K Neutral 4/10 Entry $119.47 to $121.29 Now $121.34 +1.57% ▲ +1.52% +1.80% vs SPY
- Sep 30, 20266w ago Press Release Neutral 1/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Sep 30, 20266w ago Court Ruling Neutral 3/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Aug 18, 202612w ago 8-K Neutral 3/10 Entry $104.65 to $108.32 Now $121.34 +15.95% ▲ +3.51% +3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers